What is the level of liabilities of Neovacs this year?
Neovacs has a debt balance of 3.72 M EUR this year.
Neovacs Liabilities 2025
Neovacs Liabilities
3.72 M EUR
Ticker
ALNEV.PA
ISIN
FR001400MV37
WKN
A1CVKR
In 2025, Neovacs's total liabilities amounted to 3.72 M EUR, a -27.49% difference from the 5.13 M EUR total liabilities in the previous year.
Neovacs Aktienanalyse
What does Neovacs do?
Neovacs ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Neovacs's Liabilities
Neovacs's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Neovacs's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Neovacs's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Neovacs's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Neovacs’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Neovacs stock
What were the liabilities of Neovacs compared to the previous year?
The liabilities of Neovacs have increased by -27.49% dropped compared to the previous year.
What are the consequences of high debt for investors of Neovacs?
High liabilities can pose a risk for investors of Neovacs, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Neovacs?
Low liabilities mean that Neovacs has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Neovacs affect the company?
An increase in liabilities of Neovacs can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Neovacs affect the company?
A decrease in the liabilities of Neovacs can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Neovacs?
Some factors that can influence the liabilities of Neovacs include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Neovacs so important for investors?
The liabilities of Neovacs are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Neovacs take to modify the liabilities?
To change its liabilities, Neovacs can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Neovacs pay?
Over the past 12 months, Neovacs paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neovacs is expected to pay a dividend of 0 EUR.
What is the dividend yield of Neovacs?
The current dividend yield of Neovacs is .
When does Neovacs pay dividends?
Neovacs pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Neovacs?
Neovacs paid dividends every year for the past 0 years.
What is the dividend of Neovacs?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Neovacs located?
Neovacs is assigned to the 'Health' sector.
Wann musste ich die Aktien von Neovacs kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Neovacs from 3/7/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 3/7/2025.
When did Neovacs pay the last dividend?
The last dividend was paid out on 3/7/2025.
What was the dividend of Neovacs in the year 2024?
In the year 2024, Neovacs distributed 0 EUR as dividends.
In which currency does Neovacs pay out the dividend?
The dividends of Neovacs are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Neovacs
Our stock analysis for Neovacs Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neovacs Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
